Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
iX Biopharma Ltd. ( (SG:42C) ) just unveiled an announcement.
iX Biopharma has addressed a shareholder query ahead of its extraordinary general meeting on 8 May 2026, clarifying the terms of performance shares granted to executive Mr. Eddy Lee Yip Hang. The company referred investors to its earlier shareholder letter for full rationale while confirming that vesting is governed by its established performance share plan.
The company stated that the performance shares awarded to Mr. Lee are not tied to specific performance targets and will vest automatically on pre-set dates if time-based eligibility conditions are met. This clarification offers shareholders greater transparency on executive compensation and may influence voting decisions at the upcoming meeting as well as perceptions of the firm’s remuneration governance.
The most recent analyst rating on (SG:42C) stock is a Buy with a S$1.00 price target. To see the full list of analyst forecasts on iX Biopharma Ltd. stock, see the SG:42C Stock Forecast page.
More about iX Biopharma Ltd.
iX Biopharma Ltd., incorporated in Singapore, operates in the biopharmaceutical industry through a group structure. The company focuses on developing and commercialising pharmaceutical products, and is listed on the Singapore Exchange Catalist board with UOB Kay Hian acting as its sponsor.
Average Trading Volume: 19,434,954
Technical Sentiment Signal: Buy
Current Market Cap: S$399.3M
Learn more about 42C stock on TipRanks’ Stock Analysis page.